ORIC
Oric Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$993.50M
P/E Ratio
—
EPS
$-1.46
Beta
1.36
52W High
$14.93
52W Low
$4.19
50-Day MA
$11.54
200-Day MA
$11.04
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-141.78M |
| Operating Margin | 0.00% |
| Return on Equity | -41.30% |
| Return on Assets | -26.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.90 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $112.01M |
| Float | $67.57M |
| % Insiders | 6.51% |
| % Institutions | 117.84% |
Analyst Ratings
Consensus ($21.00 target)
2
Strong Buy12
Buy1
HoldData last updated: 4/8/2026